focus -WSS

focus

author：entertainment 2025-09-07 17:19:57 - browse：4

Pascal Soriot - Senate Finance Committee — AstraZeneca CEO Pascal Soriot Jacquelyn Martin/AP

LONDON — Medicare’s first-ever drug pricing negotiations are officially underway. But neither government officials nor drugmakers are wanting to show their cards, at least publicly.

Last week, Medicare made its first offers to the makers of the 10 products subject to negotiation, though it said it would be up to the companies to discuss the proposals. On Thursday, at a press briefing at which they presented their 2023 earnings, AstraZeneca executives also played coy about the bargaining over the price of the company’s diabetes drug Farxiga.

“We have received the first offer, but as you can imagine, we will not disclose what the offer is,” Ruud Dobber, the company’s executive vice president of biopharmaceuticals business, said at the event, held at the London Stock Exchange. “We are in active negotiation, and it will be a few rounds of discussions” with Medicare.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Gene editing the human germline: What are the risks?

explore

knowledge

WSS

Readout Newsletter: Bluebird, CVS, Contineum

The strange history of BMI, the body mass index

Positive childhood experiences can help future health

The simple reason for the increase in autism diagnosis

The sun may be out, but guns are not. A lawsuit challenges a new gun ban on Hawaii beaches

Illumina to lay off 10% of research and development team

entertainment

focus

entertainment

Heart attack and stroke risk calculators need revising

The simple reason for the increase in autism diagnosis

Moonlake's readout produced a cash windfall. Risks remain

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Guidelines to prevent youth baseball injuries need more muscle

U.K. researchers warn about biases in medical devices, algorithms

Hollywood unions extend contract negotiations for actors

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

In age of alternative facts, a scholarly course on calling out crap

SCOTUS questions limit to govt efforts to fight misinformation

knowledge

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

Here's how to stay safe from wildfire smoke amid reduced air quality

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

Positive childhood experiences can help future health

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

explore

knowledge

hotspot

entertainment